Area of research
Pulmonary and Respiratory Medicine · Physiology
Research interest
Research interests include Respiratory and Cough-Related Research, Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, and Pediatric health and respiratory diseases.
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)
Linking mucus plugs and chronic bronchitis to bronchodilator responsiveness in young adult smokers: BEACON cohort
Agreement between chronic bronchitis definitions in young adult smokers: BEACON Cohort
Using chronic bronchitis symptoms to identify mucus plugging in young adult smokers: BEACON cohort
The Clinical Approach to Chronic Cough
British Thoracic Society Clinical Statement on chronic cough in adults
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Cough hypersensitivity and chronic cough
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
Global Physiology and Pathophysiology of Cough
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
Treatment of Interstitial Lung Disease Associated Cough
Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial
Chronic Cough Due to Gastroesophageal Reflux in Adults
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease
Treatment of Unexplained Chronic Cough
Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD 2–4)
Expert opinion on the cough hypersensitivity syndrome in respiratory medicine
A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response
Antitussive Drugs—Past, Present, and Future
Tools for Assessing Outcomes in Studies of Chronic Cough